Perspectives, issues and solutions in RNAi therapy: the expected and the less expected
Achim AIGNER | University of Leipzig, Leipzig | Institute of Pharmacology, Pharmacy and Toxicology | Research profile
Achim AIGNER | University of Leipzig, Leipzig | Institute of Pharmacology, Pharmacy and Toxicology | Research profile
UNIVERSITÄT LEIPZIG (@UniLeipzig) / Twitter
Achim AIGNER | University of Leipzig, Leipzig | Institute of Pharmacology, Pharmacy and Toxicology | Research profile
Achim AIGNER | University of Leipzig, Leipzig | Institute of Pharmacology, Pharmacy and Toxicology | Research profile
Achim AIGNER | University of Leipzig, Leipzig | Institute of Pharmacology, Pharmacy and Toxicology | Research profile
Module III – CAS in Radiopharmaceutical Chemistry/Radiopharmacy | ETH Zurich
SiSaf and the University of Leipzig Partner to Develop Bio-Courier Targeted miRNA for the Treatment of Pancreatic Cancer
MicroRNAs (miRNAs) in Colorectal Cancer: From Aberrant Expression Towards Therapy
Loop | Achim Aigner
SiRNA-transfection of SKOV-3-Luc cells with the Biontex K2® Transfection System Dipl.-Chem. Alexander Ewe, Prof. Achim Aigner U
Achim AIGNER | University of Leipzig, Leipzig | Institute of Pharmacology, Pharmacy and Toxicology | Research profile
Mitarbeiter des Rudolf-Boehm-Institutes
Achim AIGNER | University of Leipzig, Leipzig | Institute of Pharmacology, Pharmacy and Toxicology | Research profile
Achim AIGNER | University of Leipzig, Leipzig | Institute of Pharmacology, Pharmacy and Toxicology | Research profile
Analysis of cellular and molecular antitumor effects upon inhibition of SATB1 in glioblastoma cells
Achim Aigner | Leipzig University, Germany | Pharmaceutica 2017 | Conferenceseries
Mitarbeiter des Rudolf-Boehm-Institutes
Achim AIGNER | University of Leipzig, Leipzig | Institute of Pharmacology, Pharmacy and Toxicology | Research profile
Mitarbeiter des Rudolf-Boehm-Institutes
